NIT-110 (Solid tumors) - Clinical Trial

What is the Purpose of this Study?

We are doing this study to find out if an experimental drug called NT-17 is a safe and effective treatment for your cancer.

What is the Condition Being Studied?

Relapsed/Refractory Advanced Solid Tumors

Who Can Participate in the Study?

Adults who are diagnosed with:
- Triple negative breast cancer; OR
- Small cell lung cancer; OR
- Ovarian cancer

For more information about who can join this study, please contact the study team at CCI-TrialReferrals@duke.edu or 919-681-6468.

Age Group
Adults

What is Involved?

If you choose to join this study, you will:
- Receive the study drug (NT-17) alone or in combination with Pembrolizumab by IV
- Have physical exams, blood and urine tests
- Have imaging scans (CT and/or MRI)
- Have heart scans (ECG)
- Give tumor tissue

Study Details

Full Title
An Open-label Phase 1b/2a Study of NT-I7 (efineptakin alfa) in Combination with Pembrolizumab in Subjects with Relapsed/Refractory Advanced Solid Tumors
Principal Investigator
Christopher Hoimes
Protocol Number
IRB: PRO00105543
NCT: NCT04332653
Phase
Phase I/II
ClinicalTrials.gov
Enrollment Status
Open for Enrollment
Participate
Contact the Duke Recruitment Innovation Center
MyResearchPartners@duke.edu
or
919-681-5698